The estimated Net Worth of Javier Rodriguez is at least 4.82 千$ dollars as of 14 June 2024. Mr Rodriguez owns over 1,083 units of BioXcel Therapeutics Inc stock worth over 4,815$ and over the last 4 years he sold BTAI stock worth over 0$.
Mr has made over 7 trades of the BioXcel Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 1,083 units of BTAI stock worth 596$ on 14 June 2024.
The largest trade he's ever made was exercising 5,000 units of BioXcel Therapeutics Inc stock on 14 May 2023 worth over 2,750$. On average, Mr trades about 1,136 units every 42 days since 2021. As of 14 June 2024 he still owns at least 8,755 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Mr Rodriguez stock trades at the bottom of the page.
Javier Rodriguez is the Sr. VP, Chief Legal Officer & Corp. Sec. at BioXcel Therapeutics Inc.
Mr Rodriguez is 49, he's been the Sr. VP、 Chief Legal Officer & Corp. Sec. of BioXcel Therapeutics Inc since . There are 13 older and 1 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.
Javier's mailing address filed with the SEC is C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN, CT, 06511.
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over 63,244,788$ worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth 321,105$ . The most active insiders traders include Vimal Bio Xcel Holdings, In...、Vimal Mehta、Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of 29,814$. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth 413$.
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include: